EHang Holdings Ltd - ADR vs TransMedics Group Inc — how do they compare? EHang Holdings Ltd - ADR trades at $5.7 (market cap $437.63M), while TransMedics Group Inc trades at $86.79 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 7.1× EHang Holdings Ltd - ADR's market cap, and TransMedics Group Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| EH | TMDX | |
|---|---|---|
Market Cap | $437.63M | $3.10B |
Sector | Industrials | Technology |
52-Week High | $19.44 | $150.42 |
52-Week Low | $4.90 | $61.99 |
Enterprise Value | $376.84M | $3.49B |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.79, up 1.76% today, with a mixed technical signal (bullish overall, bearish moving averages). The company reported Q1 2026 revenue of $418M, flat year-over-year, but net income margin remains deeply negative at -77.56%. Recent news includes the EH216-S completing Central Asia's first pilotless eVTOL flight in Kazakhstan (GlobeNewsWire, August 10, 2026), highlighting operational progress amid financial challenges.
Outlook is cautious; the stock faces significant execution risk with persistent losses and high cash burn, but analyst consensus price target of $6.97 offers modest upside. Investment opportunity hinges on successful commercialization of eVTOL technology, while risks include intense competition, regulatory hurdles, and reliance on financing to sustain operations.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Trailing returns across standard periods
Latest headlines on both assets
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →